Last reviewed · How we verify
PRP autologous — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
PRP autologous (PRP autologous) — Vissum, Instituto Oftalmológico de Alicante.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PRP autologous TARGET | PRP autologous | Vissum, Instituto Oftalmológico de Alicante | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PRP autologous CI watch — RSS
- PRP autologous CI watch — Atom
- PRP autologous CI watch — JSON
- PRP autologous alone — RSS
Cite this brief
Drug Landscape (2026). PRP autologous — Competitive Intelligence Brief. https://druglandscape.com/ci/prp-autologous. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing